-
1 Comment
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the sector with a price to sales ratio of 0.0.
Based on the above factors, 4D pharma plc gets an overall score of 1/5.
| Exchange | OTCMKTS |
|---|---|
| CurrencyCode | USD |
| ISIN | None |
| Industry | |
| Sector |
| Beta | 2.84 |
|---|---|
| Target Price | None |
| PE Ratio | None |
| Market Cap | 188M |
| Dividend Yield | None |
4D pharma plc, together with its subsidiaries, engages in the research, development, and production of live biotherapeutic products. The company develops therapeutic candidates, such as MRx0518; MRx-4DP000 for the treatment of asthma and COVID-19; MRx0029 the treatment of central nervous system disorders; Blautix for irritable bowel syndrome; and Thetanix for pediatric crohn's disease. It also develops products candidates, including MRx1299 for solid tumors, MRx0005 for neurodegeneration, MRx0006 for rheumatoid arthritis, and MRx0002 for multiple sclerosis. The company develops MicroRx platform to discover new LBP candidates for major diseases. 4D pharma plc has a collaboration agreement with Merck & Co., Inc. to conduct a clinical trial evaluating the combination of Keytruda and MRx0518 in patients with solid tumors. The company was formerly known as Schosween 18 Limited. 4D pharma plc was incorporated in 2014 and is headquartered in Leeds, the United Kingdom.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for LBPSW using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
